Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults

Zheng, Xiaoya; Gong, Lei; Luo, Rong; Chen, Hua; Peng, Bin; Ren, Wei; Wang, Yonghong

doi:10.1186/s12944-017-0531-5

Cited by 54 publications

(44 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subgroup analyses revealed the association between SUA changing trajectory and NAFLD incidence was not affected by age and sex. Indeed, the previous studies reported that the relationship between SUA and NAFLD development could be sex-specific [35][36][37][38], and that the mechanism behind the sex differences remains unclear. But our study was first to found that SUA changing trajectory was associated with NAFLD incidence independently of sex.…”

Section: Discussionmentioning

confidence: 99%

Changing trajectories of serum uric acid and risk of non-alcoholic fatty liver disease: a prospective cohort study

Kang

et al. 2020

J Transl Med

View full text Add to dashboard Cite

Background: It is unclear the role of longitudinal trajectory of serum uric acid (SUA) on the development of nonalcoholic fatty liver disease (NAFLD). We aimed to determine whether longitudinal SUA trajectories are associated with the risk of new-onset NAFLD. Methods:We explored the relationship between SUA trajectories and NAFLD in a cohort including 3822 participants. Individual's SUA trajectories from 2012 to 2014 were defined using group-based trajectory modeling analysis in four distinct patterns: trajectory 1 (n = 991, 25.93%), trajectory 2 (n = 1421, 37.18%), trajectory 3 (n = 1156, 30.22%), and trajectory 4 (n = 254, 6.67%). The logistic regression model was used to evaluate the association between SUA changing trajectories and subsequent NAFLD until 2016. Dose-response relationship between SUA changing trajectories and NAFLD risk was evaluated through the testing of trajectory groups as a continuous variable. Results:The 2-year incidence of NAFLD was 13.27%. Compared with trajectory 1, the adjusted odds risk for NAFLD development was in a dose-response relationship as follows: 1.27 (95% CI 0.91-1.78) for trajectory 2, 1.89 (95% CI 1.29-2.75) for trajectory 3, and 2.34 (95% CI 1.43-3.83) for trajectory 4. And this dose-response relationship was not affected by age, sex, and abdominal obesity. Conclusions:Higher SUA changing trajectory is a risk factor for NAFLD. This finding highlights the importance of paying attention to SUA changing trajectory on the detection and prevention of NAFLD.

show abstract

Section: Discussionmentioning

confidence: 99%

Changing trajectories of serum uric acid and risk of non-alcoholic fatty liver disease: a prospective cohort study

Kang

et al. 2020

J Transl Med

View full text Add to dashboard Cite

show abstract

“…For example, Zheng et al (19) collected 95924 people from the First Affiliated Hospital of Chongqing Medical University during 2011 to 2014, they found a positive relationship between the concentration of uric acid and the developing of NAFLD, justified the age, BMI and waistline. Fu et al (20) carried out a cross-section study which 5628 people included.…”

Section: Discussionmentioning

confidence: 99%

Influence of different concentrations of uric acid on oxidative stress in steatosis hepatocytes

Cheng

Yang²,

Zhou

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

Abstract. The development of nonalcoholic fatty liver disease (NAFLD) is caused by the steatosis of hepatocytes, which induces oxidative stress (OS). Thus, OS has an important role in the development of NAFLD. In the present study, the L-02 hepatocyte cell line was used to develop a steatosis cell model. The best model was determined using an MTT assay and the triglyceride levels. Model cells were treated with high concentrations of uric acid (UA; 0, 5, 10, 20 and 30 mg/dl) for 24, 48, 72 and 96 h. Indicators of oxidation were then measured, which included total superoxide dismutase (SOD), malonaldehyde (MDA) and reduced glutathione (GSH), and the transcriptional and translational levels of SOD1 and γ-glutamate-cysteine ligase (γ-GCLC) were also determined. In addition, the intracellular levels of aspartate aminotransferase and alanine aminotransferase (ALT) were detected. The activity of SOD1 decreased over time and the result was supported by the results of western blotting. The transcriptional levels of SOD1 in model cells was significantly higher than untreated cells at 48 h. With the decreased levels of SOD1 and GSH, MDA increased in a time-dependent manner. The content of GSH decreased with time as well, which was also reflected in the results of western blotting. The transcriptional levels of γ-GCLC in all UA-treated groups were lower when compared with those observed in the model group. The activity of ALT tended to increase, depending on the duration of treatment. Treatment with 5 and 10 mg/dl UA had an antioxidative effect on the model cells, and 30 mg/dl UA treatment for 48 h increased OS in the cells.

show abstract

“…Gout is a chronic inflammatory disease characterized by recurrent joint inflammation and dysfunction caused by purine metabolism imbalance and elevated serum uric acid (sUA) whose prevalence continues to go up worldwide. As a chronic systemic inflammatory disease, gout often concurs with comorbidities such as dyslipidemia, cardiovascular disease, fatty liver disease, and renal disease [1,2]. For example, hypertriglyceridemia is more frequently observed in gouty patients than non-gouty individuals [3].…”

Section: Introductionmentioning

confidence: 99%

The comparison of dyslipidemia and serum uric acid in patients with gout and asymptomatic hyperuricemia: a cross-sectional study

et al. 2020

View full text Add to dashboard Cite

Background: Dyslipidemia often concurs with hyperuricemia. Our study was to discover different lipid levels of gout and asymptomatic hyperuricemia and the predictors of sUA (serum uric acid) levels. Methods: A cross-sectional study was performed to collect demographic, clinical variables, comorbidities and laboratory testing in patients with gout and asymptomatic hyperuricemia. Group comparison was performed with Student's t-test or Mann Whitney U test for continuous variables and chi-squared tests for categorical variables (Fisher's exact test where appropriate) and to screen potential risk factors. Correlation of sUA levels with demographic and biochemical variables were performed by using correlation analysis. The variable with s p-value less than 0.20 during the group comparison or clinical relevance was introduced into the stepwise multiple regression model. Results: Six hundred fifty-three patients with gout and 63 patients with asymptomatic hyperuricemia (> 420 μmol/L in male and > 360 μmol/L in female) were enrolled, including 553 (84.7%) males. The mean age was 47.8 ± 16.0 years old. Elevated total cholesterol (TC) was observed in 173 (26.5%) cases with gout. Increased triglycerides (TG) and low-density lipoprotein (LDL-C) levels were observed in 242 (37.1%) cases and 270 (41.3%) cases with gout, individually. In contrast, elevated TC, TG and LDL-C levels were observed in 10 (15.9%) cases, 30 (47.6%) cases and 22 (34.9%) cases with hyperuricemia, individually. Significant differences were found in age, serum creatine, TC and erythrocyte sedimentation rate (ESR) between gout and asymptomatic hyperuricemia groups (p < 0.05). In patients with asymptomatic hyperuricemia, 12 (19.0%) patients had hypertension and 5 (7.9%) suffered from coronary heart diseases. Male (B = -112.7, p < 0.001), highdensity lipoprotein (HDL-C) (B = -60.797, p = 0.013), body mass index (BMI) (B = 5.168, p = 0.024), age (B = -3.475, p = 0.006), age of hyperuricemia onset (B = 2.683, p = 0.032), and serum creatine (B = 0.534, p < 0.001) were predictors of sUA levels in gout patients (adjusted R 2 = 28.7%). Conclusions: Dyslipidemia is more commonly seen in patients with gout, compared to asymptomatic hyperuricemia. HDL-C is a protective predictor of sUA levels in gout.

show abstract

Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults

Cited by 54 publications

References 30 publications

Changing trajectories of serum uric acid and risk of non-alcoholic fatty liver disease: a prospective cohort study

Changing trajectories of serum uric acid and risk of non-alcoholic fatty liver disease: a prospective cohort study

Influence of different concentrations of uric acid on oxidative stress in steatosis hepatocytes

The comparison of dyslipidemia and serum uric acid in patients with gout and asymptomatic hyperuricemia: a cross-sectional study

Contact Info

Product

Resources

About